The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans

Circulation: Cardiovascular Genetics

Volumn 6, Issue 1, 2013, Pages 54-62

  Singaraja, Roshni R ^a,j,k   Sivapalaratnam, Suthesh ^b   Hovingh, Kees ^b   Dubé, Marie Pierre ^c   Castro Perez, José ^d   Collins, Heidi L ^e   Adelman, Steven J ^e   Riwanto, Meliana ^f   Manz, Jasmin ^f   Hubbard, Brian ^d   Tietjen, Ian ^a   Wong, Kenny ^d   Mitnaul, Lyndon J ^d   Van Heek, Margaret ^d   Lin, Linus ^d   Roddy, Thomas A ^d   McEwen, Jason ^a   Dallinge Thie, Geesje ^b   Van Vark Van Der Zee, Leonie ^g   Verwoert, Germaine ^g   Winther, Michael ^a   Van Duijn, Cornelia ^g   Hofman, Albert ^g   Trip, Mieke D ^b   Marais, A David ^h   Asztalos, Bela ⁱ   Landmesser, Ulf ^f   Sijbrands, Eric ^g   Kastelein, John J ^b   Hayden, Michael R ^k   more..

^a Xenon Pharmaceuticals Inc   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MONTREAL HEART INSTITUTE   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Vascular Strategies LLC   (United States)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ TUFTS UNIVERSITY   (United States)

^j NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Cardiovascular disease; Genetics; High density lipoprotein cholesterol; Lipids

Indexed keywords

APOLIPOPROTEIN B; ENDOTHELIAL LIPASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CHOLESTEROL, HDL; COHORT STUDIES; CORONARY ARTERY DISEASE; HETEROZYGOTE; HUMANS; LIPASE; MUTATION, MISSENSE;

EID: 84878041582     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.111.962613     Document Type: Review

References (43)

1. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag. 2010;6:525-539.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Highdensity lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
3. von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care. 2005;8:147-152.
4. Rader DJ, Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol. 2000;11:141-147.
5. Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, et al. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 2003;108:2121-2126.
6. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 2002;43:921-929.
7. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 2002;106:1321-1326.
8. Edmondson AC, Brown RJ, Kathiresan S, Cupples LA, Demissie S, Manning AK, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042-1050.
9. Ishida T, Choi SY, Kundu RK, Spin J, Yamashita T, Hirata K, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem. 2004;279:45085-45092.
10. Ko KW, Paul A, Ma K, Li L, Chan L. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res. 2005;46:2586-2594.
11. Mitnaul LJ, Tian J, Burton C, Lam MH, Zhu Y, Olson SH, et al. Fluorogenic substrates for high-throughput measurements of endothelial lipase activity. J Lipid Res. 2007;48:472-482.
12. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high-density lipoprotein: how much versus how good. J Atheroscler Thromb. 2008;15:52-62.
13. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
14. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708.
15. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563.
16. Arsenault BJ, Lemieux I, Després JP, Gagnon P, Wareham NJ, Stroes ES, et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis. 2009;206:276-281.
17. Agnani G, Marcel YL. Cholesterol efflux from fibroblasts to discoidal lipoproteins with apolipoprotein A-I (LpA-I) increases with particle size but cholesterol transfer from LpA-I to lipoproteins decreases with size. Biochemistry. 1993;32:2643-2649.
18. Davidson WS, Lund-Katz S, Johnson WJ, Anantharamaiah GM, Palgunachari MN, Segrest JP, et al. The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein. J Biol Chem. 1994;269:22975-22982.
19. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol. 2009;24:553-572.
20. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256:482-490.
21. Coronary Artery Disease Consortium, Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol. 2009;29:774-780.
22. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5A-10A.
23. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
24. Badellino KO, Wolfe ML, Reilly MP, Rader DJ. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 2006;3:e22.
25. Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J. 2010;74:2263-2270.
26. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, Tietge UJ. Scavenger receptor BI-mediated selective uptake is required for the remodeling of high-density lipoprotein by endothelial lipase. J Biol Chem. 2009;284:6093-6100.
27. Jin W, Wang X, Millar JS, Quertermous T, Rothblat GH, Glick JM, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 2007;6:129-136.
28. Brown RJ, Lagor WR, Sankaranaravanan S, Yasuda T, Quertermous T, Rothblat GH, et al. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Circ Res. 2010;107:357-364.
29. Shimizu M, Kanazawa K, Hirata K, Ishida T, Hiraoka E, Matsuda Y, et al. Endothelial lipase gene polymorphism is associated with acute myocardial infarction, independently of high-density lipoprotein-cholesterol levels. Circ J. 2007;71:842-846.
30. Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, et al. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. J Lipid Res. 2008;49:369-375.
31. Jensen MK, Rimm EB, Mukamal KJ, Edmondson AC, Rader DJ, Vogel U, et al. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J. 2009;30:1584-1589.
32. Vergeer M, Cohn DM, Boekholdt SM, Sandhu MS, Prins HM, Ricketts SL, et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis. 2010;211:558-564.
33. Mank-Seymour AR, Durham KL, Thompson JF, Seymour AB, Milos PM. Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. Biochim Biophys Acta. 2004;1636:40-46.
34. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161-169.
35. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713.
36. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
37. Ishida T, Yasuda T, Sun L, Hirata K-I. Role of endothelial lipase in HDL metabolism and atherosclerosis in humans. Atherosclerosis Supplements. 2011;12:1-11.
38. Rogler G, Trümbach B, Klima B, Lackner KJ, Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol. 1995;15:683-690.
39. Duong M, Collins HL, Jin W, Zanotti I, Favari E, Rothblat GH. Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol. 2006;26:541-547.
40. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
41. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-2191.
42. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
43. Castro-Perez J, Previs SF, McLaren DG, Shah V, Herath K, Bhat G, et al. In vivo D2O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS. J Lipid Res. 2011;52:159-169.